287 related articles for article (PubMed ID: 25100843)
1. Coronaviruses resistant to a 3C-like protease inhibitor are attenuated for replication and pathogenesis, revealing a low genetic barrier but high fitness cost of resistance.
Deng X; StJohn SE; Osswald HL; O'Brien A; Banach BS; Sleeman K; Ghosh AK; Mesecar AD; Baker SC
J Virol; 2014 Oct; 88(20):11886-98. PubMed ID: 25100843
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Antiviral β-d-
Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
[TBL] [Abstract][Full Text] [Related]
3. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
[TBL] [Abstract][Full Text] [Related]
4. Proofreading-Deficient Coronaviruses Adapt for Increased Fitness over Long-Term Passage without Reversion of Exoribonuclease-Inactivating Mutations.
Graepel KW; Lu X; Case JB; Sexton NR; Smith EC; Denison MR
mBio; 2017 Nov; 8(6):. PubMed ID: 29114026
[TBL] [Abstract][Full Text] [Related]
5. Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors.
Jiao Z; Yan Y; Chen Y; Wang G; Wang X; Li L; Yang M; Hu X; Guo Y; Shi Y; Peng G
J Virol; 2022 Sep; 96(17):e0090722. PubMed ID: 36000844
[TBL] [Abstract][Full Text] [Related]
6. Murine coronavirus ubiquitin-like domain is important for papain-like protease stability and viral pathogenesis.
Mielech AM; Deng X; Chen Y; Kindler E; Wheeler DL; Mesecar AD; Thiel V; Perlman S; Baker SC
J Virol; 2015 May; 89(9):4907-17. PubMed ID: 25694594
[TBL] [Abstract][Full Text] [Related]
7. Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses.
Kim Y; Shivanna V; Narayanan S; Prior AM; Weerasekara S; Hua DH; Kankanamalage AC; Groutas WC; Chang KO
J Virol; 2015 May; 89(9):4942-50. PubMed ID: 25694593
[TBL] [Abstract][Full Text] [Related]
8. Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity.
Stobart CC; Sexton NR; Munjal H; Lu X; Molland KL; Tomar S; Mesecar AD; Denison MR
J Virol; 2013 Dec; 87(23):12611-8. PubMed ID: 24027335
[TBL] [Abstract][Full Text] [Related]
9. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors.
Kilianski A; Mielech AM; Deng X; Baker SC
J Virol; 2013 Nov; 87(21):11955-62. PubMed ID: 23986593
[TBL] [Abstract][Full Text] [Related]
10. Lineage A Betacoronavirus NS2 Proteins and the Homologous Torovirus Berne pp1a Carboxy-Terminal Domain Are Phosphodiesterases That Antagonize Activation of RNase L.
Goldstein SA; Thornbrough JM; Zhang R; Jha BK; Li Y; Elliott R; Quiroz-Figueroa K; Chen AI; Silverman RH; Weiss SR
J Virol; 2017 Mar; 91(5):. PubMed ID: 28003490
[TBL] [Abstract][Full Text] [Related]
11. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.
Smith EC; Blanc H; Surdel MC; Vignuzzi M; Denison MR
PLoS Pathog; 2013 Aug; 9(8):e1003565. PubMed ID: 23966862
[TBL] [Abstract][Full Text] [Related]
12. A chimeric virus-mouse model system for evaluating the function and inhibition of papain-like proteases of emerging coronaviruses.
Deng X; Agnihothram S; Mielech AM; Nichols DB; Wilson MW; StJohn SE; Larsen SD; Mesecar AD; Lenschow DJ; Baric RS; Baker SC
J Virol; 2014 Oct; 88(20):11825-33. PubMed ID: 25100850
[TBL] [Abstract][Full Text] [Related]
13. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
[TBL] [Abstract][Full Text] [Related]
14. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.
Li P; Kim Y; Dampalla CS; Nhat Nguyen H; Meyerholz DK; Johnson DK; Lovell S; Groutas WC; Perlman S; Chang K-O
mBio; 2024 Feb; 15(2):e0287823. PubMed ID: 38126789
[TBL] [Abstract][Full Text] [Related]
15. The nsp1, nsp13, and M proteins contribute to the hepatotropism of murine coronavirus JHM.WU.
Zhang R; Li Y; Cowley TJ; Steinbrenner AD; Phillips JM; Yount BL; Baric RS; Weiss SR
J Virol; 2015 Apr; 89(7):3598-609. PubMed ID: 25589656
[TBL] [Abstract][Full Text] [Related]
16. Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor.
O'Brien A; Chen DY; Hackbart M; Close BJ; O'Brien TE; Saeed M; Baker SC
Virology; 2021 Apr; 556():73-78. PubMed ID: 33548599
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Coronavirus Temperature-Sensitive Mutants Reveals an Interplay between the Macrodomain and Papain-Like Protease Impacting Replication and Pathogenesis.
Deng X; Mettelman RC; O'Brien A; Thompson JA; O'Brien TE; Baker SC
J Virol; 2019 Jun; 93(12):. PubMed ID: 30918076
[TBL] [Abstract][Full Text] [Related]
18. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor
Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K
mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640
[TBL] [Abstract][Full Text] [Related]
19. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL
Kumar V; Shin JS; Shie JJ; Ku KB; Kim C; Go YY; Huang KF; Kim M; Liang PH
Antiviral Res; 2017 May; 141():101-106. PubMed ID: 28216367
[TBL] [Abstract][Full Text] [Related]
20. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.
Shimakami T; Welsch C; Yamane D; McGivern DR; Yi M; Zeuzem S; Lemon SM
Gastroenterology; 2011 Feb; 140(2):667-75. PubMed ID: 21056040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
